Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ELOVL1 | Q9BW60 | 11/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.46 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22246763 | 0.88 | LMNA (0.63) | MAPTTSHRHTTHSD17B10L3MBTL1 | |
| SCHEMBL22828685 | 0.86 | MAPT (0.54) | MAPTTSHRHTTHSD17B10L3MBTL1 | |
| SCHEMBL23719194 | 0.83 | MAPT (0.68) | MAPTTSHRHTTHSD17B10L3MBTL1 | |
| SCHEMBL23719149 | 0.81 | MAPK10 (0.51) | MAPTHTTRAB9AALDH1A1 | |
| SCHEMBL23719173 | 0.79 | CPB1 (0.43) | MAPTHTTNPC1RAB9AALDH1A1 | |
| SCHEMBL10616565 | 0.76 | MAPT (0.50) | MAPTTSHRHTTHSD17B10L3MBTL1 | |
| SCHEMBL22828238 | 0.75 | RAB9A (0.46) | MAPTTSHRHTTKDM4ENPC1 | |
| SCHEMBL22828221 | 0.75 | RAB9A (0.48) | MAPTTSHRHTTKDM4ERAB9A | |
| SCHEMBL22828578 | 0.71 | LMNA (0.66) | MAPTTSHRHTTHSD17B10L3MBTL1 | |
| SCHEMBL10417573 | 0.70 | MAPT (0.74) | MAPTTSHRHTTHSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210236466-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236466-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | MAPT 3027/4885TSHR 4487/4885HTT 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.